NCT07134335

UBT251 Injection Phase II Clinical Study (CKD)

A Phase II Clinical Study to Evaluate the Efficacy and Safety of UBT251 Injection in Obese/Overweight Chronic Kidney Disease (CKD) Population

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 180 (estimated)
• Sponsor: The United Bio-Technology (Hengqin) Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This multicenter, randomized, double-blind, placebo-controlled phase II clinical study to evaluate the efficacy and safety of UBT251 injection in obese/overweight chronic kidney disease (CKD) population

Conditions

• Obesity &Amp; Overweight
• Chronic Kidney Disease

Interventions

Type	Name	Description
DRUG	UBT251	Subcutaneous injection once weekly
DRUG	UBT251	Subcutaneous injection once weekly
DRUG	UBT251	Subcutaneous injection once weekly

Timeline

• Start date: 2025-09-01
• Primary completion: 2030-07-11
• Completion: 2030-07-11
• First posted: 2025-08-21
• Last updated: 2025-11-25

Locations

1 site across 1 country: China